| (P141) |
Evaluation of hemorheorogical profiles in patients with no-reperfusion phenomenon in acute ST elevation myocardial infarction treated by primary percutaneuous coronary intervention. |
|
J. Wasilewski, B. Turczynski, V. Kowalik, T. Osadnik, L. Polonski (Zabrze, PL) |
| (P142) |
EDHF is a potent inhibitor of platelet adhesion in vivo. |
|
S. Lehrer, N. Hellwig, M. Buerkle, H-Y. Sohn, F. Krötz, U. Pohl (München, DE) |
| (P143) |
The plasmatic homocysteine increase alters tisular plasminogen activator and plasminogen activator INHIBITOR-1 relationship in patients suffering from homocistinuria. |
|
A. Córdoba Porras, L.A. Villa Lopez (Medellín, CO) |
| (P144) |
Heterogeneity of tissue-derived anticoagulant effects on plasma thrombin generation. |
|
K. Frederix, R. van Oerle, D. Fens, K. Hamulyák, H.M.H. Spronk, H. ten Cate (Maastricht, NL) |
| (P145) |
Influence of oxidized LDL on VASP phosphorylation in human platelets. |
|
W. Schmid, A. Roth, E. Koller, I. Volf (Vienna, AT) |
| (P146) |
The JAK-STAT-signaling pathway is involved in platelet activation by leptin. |
|
C. Dellas, K. Schäfer, D.J. Loskutoff, S.V. Konstantinides (Göttingen, DE; La Jolla, US) |
| (P147) |
Altered clot formation and lysis in first-degree relatives of South Asian subjects with type 2 diabetes mellitus. |
|
R. Somani, A. Carter, C. Cymbalista, P. Grant (Leeds, GB) |
| (P148) |
Elevated lipoprotein(a) levels: a new biological marker of venous thromboembolic risk. |
|
F. Casals, G. Escolar, R. Deulofeu, E. Casals (Barcelona, ES) |
| (P149) |
The Losartan metabolite EXP 3179 inhibits collagen-induced platelet activation via blockade of the GPVI receptor. |
|
Chr. Grothusen, S. Kerstan, I. Konrad, Chr. Schulz, S. Umbreen, B. Schmidt, S. Massberg, B. Schieffer, M. Gawaz (Hannover, München, Darmstadt and Tübingen, DE) |
| (P150) |
Thrombin/ADP-stimulated platelets release coagulation factor XIIIA in microvesicles. |
|
P. Cordell, P. Grant, R. Pease (Leeds, GB) |